

H2 looks promising but valuations 'RICH'

CMP: INR 547
Rating: HOLD
Target Price: INR 559

| Stock Info | |
|-----------------------------|-------------------|
| BSE | 531642 |
| NSE | MARICO |
| Bloomberg | MRCO:IN |
| Reuters | MRCO.BO |
| Sector | Personal Products |
| Face Value (INR) | 1 |
| Equity Capital (INR cr) | 129 |
| Mkt Cap (INR cr) | 70,555 |
| 52w H/L (INR) | 4,004/3,318 |
| Avg Yearly Volume (in 000') | 36 |
| | |

| (As on June, 2021) | |
|--------------------|------|
| Promoters | 59.6 |
| FII | 24.9 |
| DII | 9.6 |
| Government | 0.1 |
| Public & Others | 5.8 |
| | |

| Stock Performance (%) | 3m | 6m | 12m |
|-----------------------|----|----|-----|
| Marico | 29 | 29 | 46 |
| Nifty 50 | 6 | 16 | 42 |

Marico Vs Nifty



Ruchitaa Maheshwari

<u>ruchita.maheshwari@arihantcapital.com</u> 022 67114872

Marico performance was broadly in-line with our estimates. Its Revenue of INR2,525cr was slightly lower by 0.3% of our estimates to INR2,532cr. Domestic business saw 21% volume growth on account of favourable base (14% volume decline) and broad-based performance across key segments (particularly Saffola and VAHO franchisee. All three core segments (Saffola edible oil - 12%; VAHO - 34%; Parachute - 12%) delivered strong volume led performance on back of favourable base, market share gains from unorganized sector and increased inhome consumption (more applicable to Saffola).

International business reported 21% CC revenue growth driven by favorable base as MENA/South Africa grew 74%/52% respectively. However, with rising covid cases in Bangladesh and Vietnam disappointed with 9%/16% growth on a favorable base. As per management, South Africa will witness a slowdown going forward on the back of political unrest and rising covid cases.

Gross Margin contraction (760bps) to 41% continues to increase vs 311bps contraction QoQ on account of RM inflation (Copra up 21%, Rice brand oil up 68%, LLP up 51%, HDPE up 47% YoY). However, management has guided that gross margin will improve sequentially on account of copra prices expected to remain range-bound in FY22 on YoY basis and company is intent to take price hikes in Saffola edible oil portfolio.

Marico reported EBITDA margin of 19%, a decline of 521bps YoY but 65bps better than our estimate of 18.4%. Despite higher A7P spends, decline in EBITDA margin was controlled by tight lid on operating costs and employee costs.

During FY21, the company had taken number of initiatives and has been able to save INR1.5-2bn via focussing on analytics, better resource allocation in sales and market department, SKU rationalization (25% reduction), cost transformation exercise, which it now plans to take to overseas markets (Egypt and Vietnam). Management guided to continue the same initiatives in FY22 with similar target.

<u>Valuation & Outlook:</u> Marico continues to consolidate its leadership position with market share gains across its core segments: coconut oil, value added hair oils, and super premium refined edible oils. We believe these segment possess significant headroom for category growth as well as market share gains, the short-term rural demand slowdown notwithstanding. We opine that, through attractive pricing and enhanced distribution reach, the company has the ability to drive unbranded to branded conversions and penetration at the bottom of the pyramid. In addition, the company can also experiment the premiumization category in select pockets through product innovations by delivering enhanced value to the consumer.

Marico management suggested a few critical shifts in short-term focus areas – (1) renewed focus on the core portfolio, (2) aggressiveness at the value end of the market as opposed to premium, (3) accelerated NPDs in foods and entry in the hygiene space, and (4) higher thrust on ramping up direct distribution in the rural markets.

Given the well diversified product portfolio and a strong presence of Marico in some key emerging markets that are growing faster than the domestic market and with new launches lined up, we believe the company has significant growth potential for a long term perspective.

We expect Marico to report a Revenue/EBITDA/PAT CAGR of 21%/19.1%/17.4% to INR11,775cr/INR2,255cr/INR1,658cr, over FY21-FY23E, respectively. We believe that going forward, 1) Saffola portfolio volume growth to moderate as covid tailwind recedes, 2) Foods business (INR8bn) and Digital brands (INR5bn) to have lower margin (on the account of increasing A&P spends & lower entry barrier), 3) increasing competitive intensity in the hair oil category and 4) company is entering at high base & is trading at rich valuations. We maintain HOLD rating with a TP of INR559per share (PE of 43x on FY23E). We would 'wait and watch' for more constructive entry point and comfortable valuations.

Key Concall takeaways

Business Performance

The core business continues to gain market share on MAT basis on the back of market leadership and strengthening equity. More than 90% of the portfolio gained market share on MAT basis.

➤ Urban and rural traditional channel continue to grow healthy at 17% in volume terms. E-comm grew 61%, MT 10% and CSD 56% YoY, respectively.

>Quarter started on a strong note but due to covid, April end when the mobility was impacted. This time, rural demand was impacted unlike last year.

Marico to deliver 8-10% volume growth for the next 3 quarters and international business to register double digit growth on CC basis.

A deflation starts in edible oil, company will manage margins and volume.

The company will reverse price hikes once downward trajectory in edible oils happens.

➤ Prices difference evident in Copra in India and International.

➤ Gross margin will improve QoQ and should settle down in H2FY22.

➤ Company is looking to achieve 19% operating margins.

➤ No pricing action in Parachute.

Digital brands operate like start-ups. Lot of learning curve for the company.

> Company targets INR4.5-5bn top-line by FY24 under the digital brand driven by 4-5 brands.

>Beardo to work in the combination of E-comm, D2C and MT. GT will be avoided at the moment.

➤ Saffola's incremental is due to 60% new consumers and 40% from existing consumers increasing their consumption.

To drive growth in Saffola Gold and Saffola Total.

➤ Company will be happy with high single digit growth in Saffola.

Focus on Personal care brands for building digital care business.

>Inventory management, SKU management and WFH will save costs.

>Company has the aspiration to grow Livon and Set Wet at 20% plus levels and will increase penetration.

Company is planning to expand rural distribution by 25% in next 2 years.

Company have started appointing specialized chemist based stockists / distributors in metro cities as it now broad based product portfolio (premium hair oil, skin care, honey and immunity boosting products) to offer to chemist based stores.

Parachute

Parachute Rigids grew by 12% YoY in volumes in Q1FY22, albeit on a low base. Brand continues to strengthened its presencein both core and non-core markets. However, the extended lockdowns in the core markets of South and West regions affected growth during the quarter.

>The branded coconut oil with the rigid packs gained volume market share of 80bps (MAT June 21)

General Trade & E-Com led the growth, while CSD also recovered.

The brand is well poised to sustain its good run over the medium term with focused distribution drives and improving salience in both core & non-core markets.

VAHO

➤ Value Added Hair Oils grew 34% YoY in volume terms in Q1FY22, on a weak base, which was due to billing constraints in April last year.

All key brands in the franchise posted high double-digit volume growth.

>The segment gained ~70 bps in volume market share in overall hair oils category on a MAT basis.

The company aims to sustain a double digit growth trajectory over the medium term: 1) Bottom Pyramid: on the back of continued aggressive participation, 2) Mid-Segment: driving growth through right pricing & brand renovation and, 3) Premium Segment: market share gains through innovation.

Saffola

The Saffola franchise, comprising Refined Edible Oils and Foods, had a robust quarter. The portfolio delivered 24% YoY volume growth and 60% YoY growth in value terms.

Saffola refined edible oils delivered low double-digit volume growth for the seventh consecutive quarter on the back of increased household penetration and growing relevance of healthy cooking.

➤The brand gained 450bps in volume market share to ~82% on MAT basis in the Super Premium Refined Edible Oils category.

➤Saffola Foods grew by more than 100% YoY in value terms in Q1FY22. The Oats franchise continued to ride on the increasing consciousness towards healthy eating and posted a value growth of 59% YoY in Q1FY22. The value market share of Saffola Masala Oats strengthened by ~650bps to ~94% in the flavored oats category on MAT basis.

➤ Company have an aim to achieve INR500cr in FY22E.

As per management, most of the new launches in the Foods portfolio continued to gain traction. Saffola Honey has been gaining salience across channels. The brand is gaining market share in key MT chains, has hit double-digits and consolidated above 25% in the E-Com channel. The brand continues to grow sequentially in GT as well. The company has launched a 100gm trial pack to expand distribution and aid trials.

Saffola Mealmaker: Soya Chunks has gained healthy traction since launch. The brand has tasted success in West Bengal in GT and it was extended to the rest of East and select regions in the North in Q1FY22. The brand has garnered ~14% share in MT since launch in Q3FY21.

Saffola Arogyam Chyawan Amrut: The brand has not scaled up as expected. The management is strategising by revamping the mix and expects to make some headway going forward.

Saffola Oodles has been witnessing an encouraging response on all channels. The brand is scaling up well in GT & MT, and is among the top 5 Bestsellers in the Pasta and Noodles category on Amazon. The category is INR100bn, and management is targeting 2-3% market share, can be meaningful for the company.

Male grooming and premium hair care

>The Premium Personal Care portfolio, comprising Premium Hair Nourishment and Male Grooming, recovered smartly on a YoY basis.

➤ Male Grooming came back strongly on a weak base, but still below pre-Covid levels.

➤ Beardo: The brand is tracking in line of internal aspirations and gaining tractions after the initial covid induced headwinds. The target is to close the year at a run rate of INR1bn. The company will continue brand investments and strengthening equity over the medium term.

>Livon Serums continued to witness positive traction post covid headwinds.

➤ Management expects these portfolios to be growth engines of the future, given the leadership position of our brands and low penetration of these categories.

International Business

Bangladesh

➤ The business reported 9% CC growth YoY.

➤ Parachute Coconut oil grew 4% in CC terms. Non-coconut oil portfolio grew by 20% in CC terms led by VAHO. The new product Just for Baby (baby care) and Naturale Shampoos are trending well.

As per management, Bangladesh is witnessing a rise in covid cases which can impact the business in near term.

South East Asia

The business grew % YoY on CC terms on low base.

>Vietnam saw a recovery on Home & Personal care on YoY basis and food business continued its positive momentum.

➤In June, the company had launched a hair body wash range under the brand name X-Men Clean and Fresh, including ingredients like Himalyan Salts and Korean Aloe Vera.

MENA

➤ The business reported 74% growth in CC terms led by a weak base.

South Africa business grew 52% YoY in CC terms led by low base, driven by Health Care portfolio.

>The company remains cautiously optimistic about the growth outlook. The company will drive the growth through aggressive cost management strategy.

Quarter Result

Q1FY22 Result Analysis

| Y/E March (Rscr) | Q1FY21 | Q4FY21 | Q1FY22 | YoY (%) | QoQ (%) |
|---|--------|--------|--------|---------|---------|
| Net sales | 1,925 | 2,012 | 2,525 | 31.2 | 25.5 |
| Net raw material & Purchase of finished goods | 989 | 1,124 | 1,489 | 50.6 | 32.5 |
| % of sales | 51.4 | 55.9 | 59.0 | | |
| Employee expenses | 135 | 150 | 150 | 11.1 | - |
| % of sales | 7.0 | 7.5 | 5.9 | | |
| Advertisement Expenses | 137 | 173 | 175 | 27.7 | 1.2 |
| % of sales | 7.1 | 8.6 | 6.9 | | |
| Other expenses | 197 | 246 | 230 | 16.8 | (6.5) |
| % of sales | 10.2 | 12.2 | 9.1 | | |
| Total expenditure | 1,458 | 1,693 | 2,044 | 40.2 | 20.7 |
| Operating Profit | 467 | 319 | 481 | 3.0 | 50.8 |
| OPM(%) | 24.3 | 15.9 | 19.0 | | |
| Interest | 9 | 10 | 8 | (11.1) | (20.0) |
| PBDT | 458 | 309 | 473 | 3.3 | 53.1 |
| Depreciation | 34 | 36 | 33 | (2.9) | (8.3) |
| Other income | 19 | 29 | 27 | 42.1 | (6.9) |
| Exceptional item | (64) | - | - | | |
| Share of JV/Associate less minority interest | (2) | 19 | - | | |
| РВТ | 505 | 321 | 467 | (7.5) | 45.5 |
| Tax | 117 | 56 | 102 | | |
| Effective tax rate (%) | 23.2 | 17.4 | 21.8 | | |
| Reported PAT | 388 | 265 | 365 | (5.9) | 37.7 |
| Comprehensive income | (2) | (2) | 14 | | - |
| Adjusted PAT | 386 | 263 | 379 | (1.8) | 44.1 |
| NPM(%) | 20.1 | 13.1 | 15.0 | | |
| EPS (Rs.) | 3.0 | 2.0 | 2.9 | (1.8) | 44.1 |
| Equity | 129 | 129 | 129 | - | - |

Source: Company & Arihant Research

Result declared vs Our estimates

| Y/E Mar (Rscr) | Q1FY21 | Q4FY21 | Q1FY22 | YoY (%) | QoQ (%) | Arihant Capital estimates | Variation (%) |
|----------------|--------|--------|--------|---------|---------|---------------------------|---------------|
| Net Sales | 1,925 | 2,012 | 2,525 | 31.2 | 25.5 | 2,532 | (0.3) |
| EBITDA | 467 | 319 | 481 | 3.0 | 50.8 | 466 | 3.2 |
| EBITDA (%) | 24.3 | 15.9 | 19.0 | (521) | 319 | 18.4 | 65 |
| | 200 | 265 | 265 | (5.0) | 27.7 | 256 | 2.4 |
| Reported PAT | 388 | 265 | 365 | (5.9) | 37.7 | 356 | |

Source: Company & Arihant Research

Q1FY22 - Result Update | Marico Ltd


Quarterly Result

Geography Break-up

| Y/E Mar (Rscr) | Q1FY21 | Q4FY21 | Q1FY22 | YoY (%) | QoQ (%) |
|-------------------------|--------|--------|--------|---------|---------|
| Sales | | | | | |
| India | 1,480 | 1,574 | 1,998 | 35.0 | 26.9 |
| International | 445 | 438 | 534 | 20.0 | 21.9 |
| Total | 1,925 | 2,012 | 2,532 | 31.5 | 25.8 |
| % of Sales Contribution | | | | | |
| India | 76.9 | 78.2 | 78.9 | 203 | 68 |
| International | 23.1 | 21.8 | 21.1 | (203) | (68) |
| EBIT | | | | | |
| India | 358 | 254 | 354 | (1.1) | 39.4 |
| International | 125 | 83 | 139 | 11.2 | 67.5 |
| Total | 483 | 337 | 493 | 2.1 | 46.3 |
| EBIT (%) | | | | | |
| India | 24.2 | 16.1 | 17.7 | (647) | 158 |
| International | 28.1 | 18.9 | 26.0 | (206) | 708 |
| Total | 25.1 | 16.7 | 19.5 | (562) | 272 |


Source: Company & Arihant Research


Quarter Result




■ International Growth ■ Domestic Growth 30% 25% 20% 15% 10% 5% 0% -10% OAFY129 OTHYDO 025420 035722 OAFY21 03572 -15% -20%

Source: Company & Arihant Research









Source: Company & Arihant Research


Source: Company & Arihant Research



Source: Company & Arihant Research

Quarterly Result





Source: Company & Arihant Research

Source: Company & Arihant Research

| Market Share trends | Q2FY19 | Q3FY19 | Q4FY19 | Q1FY20 | Q2FY20 | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 |
|----------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ivial ket Share trenus | QZF119 | QSF115 | Q4F113 | QIFTZU | QZF1ZU | Q3F1ZU | Q4F1ZU | QIFTZI | QZF1Z1 | QSF1ZI | Q4F1ZI | QIFTZZ |
| | | | | | | | | | | | | |
| Coconut Oil | 59% | 59% | 59% | 60% | 60% | 61% | 62% | 62% | 62% | 62% | 61% | 62% |
| | | | | | | | | | | | | |
| Saffola Super premium ROCP | 71% | 72% | 73% | 73% | 75% | 76% | 76% | 77% | 77% | 76% | 81% | 82% |
| | | | | | | | | | | | | |
| VAHO | 34% | 34% | 34% | 34% | 35% | 35% | 35% | 36% | 36% | 35% | 37% | 37% |
| | | | | | | | | | | | | |
| Saffola Oats | 29% | 29% | 29% | 30% | 31% | 32% | 33% | 34% | 34% | 33% | 38% | 39% |
| | | | | | | | | | | | | |
| Post wash leave on serum | 78% | 76% | 75% | 63% | 64% | 65% | 65% | 65% | 65% | 65% | 63% | 63% |
| | | | | | | | | | | | | |
| Hair gels/wax/creams | 62% | 61% | 60% | 60% | 60% | 59% | 59% | 59% | 59% | 59% | 57% | 58% |

Source: Company & Arihant Research

Q1FY22 - Result Update | Marico Ltd

| Income statement summary | | | | | | | | | | | |
|---|--|---|---|---|---|--|--|---|---|--|---|
| | | | | | | Balance sheet summary | | | | | |
| Y/e 31 Mar (Rs cr) | FY19 | FY20 | FY21 | FY22E | FY23E | Y/e 31 Mar (Rs cr) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Davisia | 7 224 | 7 245 | 0.040 | 10 220 | 44 775 | Equity capital | 129 | 129 | 129 | 129 | 129 |
| Revenue Net Raw Materials | 7,334 | 7,315 | 8,048 | 10,239 | 11,775 | Reserves | 2,846 | 2,894 | 3,111 | 4,314 | 5,682 |
| Advt & Promotion | 4,017 | 3,745 727 | 4,270 | 5,478 | 6,241 | Net worth | 2,975 | 3,023 | 3,240 | 4,443 | 5,811 |
| | 659 466 | | 698 | 922 717 | 1,060 795 | Minority Interest | 12 | 13 | 18 | 18 | 18 |
| Employee Cost | 466 | 478 | 570 | | | Debt | 563 | 558 | 552 | 502 | 477 |
| Other Expenses | 866 | 896 | 919 | 1,249 | 1,425 | Other non-current | 20 | 24 | 24 | 24 | 24 |
| Total Expenses | 6,008 | 5,846 | 6,457 | 8,366 | 9,520 | liabilities | 20 74 | 21 80 | 24 | 24 | 24 |
| EBITDA | 1,326 | 1,469 | 1,591 | 1,874 | 2,255 | Deferred tax liab (net) Total liabilities | 3,644 | 3,695 | 156 3,990 | 156 5,143 | 156 6,486 |
| EBITDA % | 1,320 | 20.1 | 1,551 | 18.3 | 19.2 | Total liabilities | 3,044 | 3,033 | 3,330 | 5,145 | 0,400 |
| EBITUA % | 10.1 | 20.1 | 19.8 | 10.3 | 19.2 | Fixed assets | 572 | 654 | 572 | 630 | 674 |
| Depreciation | (131) | (140) | (139) | (166) | (196) | Capital Work In Progress | 45 | 58 | 24 | 40 | 47 |
| Depreciation | (131) | (140) | (133) | (100) | (130) | Other Intangible assets | 55 | 41 | 230 | 230 | 230 |
| Interest expense | (40) | (50) | (34) | (32) | (30) | Goodwill | 503 | 538 | 613 | 613 | 613 |
| interest expense | (40) | (50) | (34) | (32) | (30) | Investments | 105 | 153 | 288 | 288 | 288 |
| Other income | 103 | 124 | 94 | 95 | 97 | Other non current assets | 429 | 376 | 447 | 512 | 589 |
| Other income | 103 | 124 | 94 | 95 | 97 | Inventories | 1,411 | 1,380 | 1,126 | 1,446 | 1,647 |
| Eventional items | | 20 | (12) | | | Sundry debtors | 517 | 539 | 388 | 626 | 720 |
| Exceptional items | 4 276 | 29 | (13) | 4 700 | 2 4 4 5 | Loans & Advances | 5 | 5 | 6 | 6 | 7 |
| Profit before tax | 1,276 | 1,452 | 1,519 | 1,789 | 2,145 | Other current assets | 320 | 348 | 239 | 313 | 360 |
| _ | (4.2.5) | (224) | (22.4) | (200) | (450) | | | | | | |
| Taxes | (126) | (331) | (324) | (389) | (468) | Sundry creditors | (944) | (978) | (1,134) | (1,464) | (1,666) |
| | | | | | | Other current liabilities & | ` , | , , | , , | , , | , , |
| Minorities and other | (1) | - | (2) | - | - | Prov | (321) | (329) | (386) | (484) | (556) |
| | | | | | | Cash | 552 | 279 | 944 | 1,592 | 2,619 |
| Reported Net profit | 1,151 | 1,121 | 1,197 | 1,399 | 1,677 | Other Financial Assets | 395 | 631 | 633 | 796 | 916 |
| Comprehensive income | -18 | 42 | 5 | 0 | 0 | Miscelleneous Exp | 0 | 0 | 0 | 0 | 0 |
| | | | | | | Total assets | 3,644 | 3,695 | 3,990 | 5,143 | 6,486 |
| Net profit | 1,133 | 1,163 | 1,202 | 1,399 | 1,677 | | | | | | |
| EPS (INR) | 8.6 | 8.4 | 9.3 | 10.7 | 12.9 | Cashflow summary | | | | | |
| Ratio analysis | | | | | | Y/e 31 Mar (Rs cr) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Y/e 31 Mar (Rs cr) | FY19 | FY20 | FY21 | FY22E | FY23E | (| | | | | |
| Growth matrix (%) | | | | | | Profit before tax | 1,276 | 1,452 | 1,519 | 1,789 | 2,145 |
| | | | | | | | | | | | |
| Revenue growth | 15.8 | (0.3) | 10.0 | 27.2 | 15.0 | Depreciation | 131 | 140 | 139 | 166 | 196 |
| | | | | | | | | | | | |
| Op profit growth | 16.5 | 10.8 | 8.3 | 17.8 | 20.3 | Tax paid | (126) | (331) | (324) | (389) | (468) |
| | | | | | | | | | | | |
| Net profit growth | 36.1 | (2.6) | 6.8 | 16.9 | 19.9 | Working capital Δ | 21 | 23 | 726 | (203) | (68) |
| Profitability ratios (%) | | | | | | | | | | | |
| | | | | | | Other operating items | (17) | (35) | (75) | - | - |
| RoCE | 36.4 | 24.0 | | | 20.0 | | | | | | |
| | | 31.0 | 33.0 | 32.2 | 29.9 | | | | | | |
| | | | 33.0 | | | Operating cashflow | 1,285 | 1,249 | 1,985 | 1,362 | 1,805 |
| RoNW | 40.3 | 36.2 | 33.0 38.4 | 32.2 35.9 | 32.3 | | • | • | • | 1,362 | |
| | | 36.2 | 38.4 | 35.9 | 32.3 | Operating cashflow Capital expenditure | 1,285 (187) | 1,249 (235) | 1,985 (23) | 1,362 (240) | 1,805 (247) |
| RoA | 40.3 30.5 | | | | | Capital expenditure | (187) | (235) | (23) | (240) | (247) |
| RoA | | 36.2 | 38.4 | 35.9 | 32.3 | | • | • | • | • | |
| ROA Per share ratios | 30.5 | 36.2 29.4 | 38.4 | 35.9 26.8 | 32.3 25.6 | Capital expenditure Free cash flow | (187) 1,098 | (235) 1,014 | (23) 1,962 | (240) 1,122 | (247) 1,558 |
| ROA Per share ratios Book value per share | | 36.2 | 38.4 | 35.9 | 32.3 | Capital expenditure | (187) | (235) | (23) | (240) | (247) |
| ROA Per share ratios Book value per share | 30.5 | 36.2 29.4 | 38.4 | 35.9 26.8 | 32.3 25.6 | Capital expenditure Free cash flow Equity raised | (187) 1,098 (698) | (235) 1,014 (1,112) | (23) 1,962 (982) | (240) 1,122 | (247) 1,558 |
| RoA Per share ratios Book value per share Valuation ratios | 30.5 | 36.2 29.4 23.4 | 38.4 30.2 25.1 | 35.9 26.8 34.4 | 32.3 25.6 45.0 | Capital expenditure Free cash flow | (187) 1,098 | (235) 1,014 | (23) 1,962 | (240) 1,122 | (247) 1,558 |
| RoA Per share ratios Book value per share Valuation ratios | 30.5 | 36.2 29.4 | 38.4 | 35.9 26.8 | 32.3 25.6 | Capital expenditure Free cash flow Equity raised Investments | (187) 1,098 (698) | (235) 1,014 (1,112) (48) | (23) 1,962 (982) (135) | (240) 1,122 (183) | (247) 1,558 (297) |
| RoA Per share ratios Book value per share Valuation ratios P/E | 30.5 23.1 61.3 | 36.2 29.4 23.4 62.9 | 38.4 30.2 25.1 59.0 | 35.9 26.8 34.4 50.4 | 32.3 25.6 45.0 42.1 | Capital expenditure Free cash flow Equity raised | (187) 1,098 (698) | (235) 1,014 (1,112) | (23) 1,962 (982) | (240) 1,122 | (247) 1,558 |
| RoA Per share ratios Book value per share Valuation ratios P/E | 30.5 | 36.2 29.4 23.4 | 38.4 30.2 25.1 | 35.9 26.8 34.4 | 32.3 25.6 45.0 | Capital expenditure Free cash flow Equity raised Investments Others | (187) 1,098 (698) 1 (257) | (235) 1,014 (1,112) (48) (169) | (23) 1,962 (982) (135) (262) | (240) 1,122 (183) - (228) | (247) 1,558 (297) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS | 30.5 23.1 61.3 55.0 | 36.2 29.4 23.4 62.9 56.0 | 38.4 30.2 25.1 59.0 52.8 | 35.9 26.8 34.4 50.4 45.1 | 32.3 25.6 45.0 42.1 37.7 | Capital expenditure Free cash flow Equity raised Investments | (187) 1,098 (698) | (235) 1,014 (1,112) (48) | (23) 1,962 (982) (135) | (240) 1,122 (183) | (247) 1,558 (297) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS | 30.5 23.1 61.3 | 36.2 29.4 23.4 62.9 | 38.4 30.2 25.1 59.0 | 35.9 26.8 34.4 50.4 | 32.3 25.6 45.0 42.1 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal | (187) 1,098 (698) 1 (257) 233 | (235) 1,014 (1,112) (48) (169) (5) | (23) 1,962 (982) (135) (262) (6) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS | 30.5 23.1 61.3 55.0 23.7 | 36.2 29.4 23.4 62.9 56.0 23.3 | 38.4 30.2 25.1 59.0 52.8 21.8 | 35.9 26.8 34.4 50.4 45.1 15.9 | 32.3 25.6 45.0 42.1 37.7 12.1 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid | (187) 1,098 (698) 1 (257) | (235) 1,014 (1,112) (48) (169) | (23) 1,962 (982) (135) (262) | (240) 1,122 (183) - (228) | (247) 1,558 (297) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA | 30.5 23.1 61.3 55.0 | 36.2 29.4 23.4 62.9 56.0 | 38.4 30.2 25.1 59.0 52.8 | 35.9 26.8 34.4 50.4 45.1 | 32.3 25.6 45.0 42.1 37.7 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal | (187) 1,098 (698) 1 (257) 233 | (235) 1,014 (1,112) (48) (169) (5) | (23) 1,962 (982) (135) (262) (6) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) | 30.5 23.1 61.3 55.0 23.7 53.1 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid | (187) 1,098 (698) 1 (257) 233 | (235) 1,014 (1,112) (48) (169) (5) | (23) 1,962 (982) (135) (262) (6) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) |
| ROA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) | 30.5 23.1 61.3 55.0 23.7 | 36.2 29.4 23.4 62.9 56.0 23.3 | 38.4 30.2 25.1 59.0 52.8 21.8 | 35.9 26.8 34.4 50.4 45.1 15.9 | 32.3 25.6 45.0 42.1 37.7 12.1 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back | (187) 1,098 (698) 1 (257) 233 | (235) 1,014 (1,112) (48) (169) (5) | (23) 1,962 (982) (135) (262) (6) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) |
| ROA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout | 30.5 23.1 61.3 55.0 23.7 53.1 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back | (187) 1,098 (698) 1 (257) 233 | (235) 1,014 (1,112) (48) (169) (5) | (23) 1,962 (982) (135) (262) (6) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) |
| ROA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout | 30.5 23.1 61.3 55.0 23.7 53.1 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy | (187) 1,098 (698) 1 (257) 233 (3) | (235) 1,014 (1,112) (48) (169) (5) (3) | (23) 1,962 (982) (135) (262) (6) (3) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) (13) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout | 30.5 23.1 61.3 55.0 23.7 53.1 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy | (187) 1,098 (698) 1 (257) 233 (3) | (235) 1,014 (1,112) (48) (169) (5) (3) | (23) 1,962 (982) (135) (262) (6) (3) | (240) 1,122 (183) (228) (50) | (247) 1,558 (297) (196) (25) (13) |
| ROA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout Tax payout Liquidity ratios | 30.5 23.1 61.3 55.0 23.7 53.1 0.2 9.9 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 22.8 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 21.3 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 21.8 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 0.8 21.8 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy Other items | (187) 1,098 (698) 1 (257) 233 (3) (23) | (235) 1,014 (1,112) (48) (169) (5) (3) 50 | (23) 1,962 (982) (135) (262) (6) (3) 91 | (240) 1,122 (183) (228) (50) (13) - | (247) 1,558 (297) (196) (25) (13) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout Tax payout Liquidity ratios | 30.5 23.1 61.3 55.0 23.7 53.1 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy Other items | (187) 1,098 (698) 1 (257) 233 (3) (23) | (235) 1,014 (1,112) (48) (169) (5) (3) 50 | (23) 1,962 (982) (135) (262) (6) (3) 91 | (240) 1,122 (183) (228) (50) (13) - | (247) 1,558 (297) (196) (25) (13) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout Tax payout Liquidity ratios Debtor days | 30.5 23.1 61.3 55.0 23.7 53.1 0.2 9.9 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 22.8 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 21.3 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 21.8 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 0.8 21.8 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy Other items Net Δ in cash | (187) 1,098 (698) 1 (257) 233 (3) (23) 351 | (235) 1,014 (1,112) (48) (169) (5) (3) - - 50 (273) | (23) 1,962 (982) (135) (262) (6) (3) 91 665 | (240) 1,122 (183) (228) (50) (13) | (247) 1,558 (297) (196) (25) (13) |
| RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout Tax payout Liquidity ratios Debtor days | 30.5 23.1 61.3 55.0 23.7 53.1 0.2 9.9 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 22.8 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 21.3 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 21.8 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 0.8 21.8 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy Other items Net Δ in cash | (187) 1,098 (698) 1 (257) 233 (3) (23) 351 | (235) 1,014 (1,112) (48) (169) (5) (3) - - 50 (273) | (23) 1,962 (982) (135) (262) (6) (3) 91 665 | (240) 1,122 (183) (228) (50) (13) | (247) 1,558 (297) (196) (25) (13) |
| RoNW RoA Per share ratios Book value per share Valuation ratios P/E P/CEPS P/B EV/EBIDTA Payout (%) Dividend payout Tax payout Liquidity ratios Debtor days Inventory days Creditor days | 30.5 23.1 61.3 55.0 23.7 53.1 0.2 9.9 | 36.2 29.4 23.4 62.9 56.0 23.3 48.1 0.3 22.8 | 38.4 30.2 25.1 59.0 52.8 21.8 43.9 0.2 21.3 | 35.9 26.8 34.4 50.4 45.1 15.9 36.9 0.9 21.8 | 32.3 25.6 45.0 42.1 37.7 12.1 30.2 0.8 21.8 | Capital expenditure Free cash flow Equity raised Investments Others Debt financing/disposal Dividends paid Equity Buy back Capital subsidy Other items Net Δ in cash Opening Cash Flow | (187) 1,098 (698) 1 (257) 233 (3) (23) 351 201 552 | (235) 1,014 (1,112) (48) (169) (5) (3) - 50 (273) 552 279 | (23) 1,962 (982) (135) (262) (6) (3) 91 665 279 | (240) 1,122 (183) (228) (50) (13) 648 944 | (247) 1,558 (297) (196) (25) (13) - 1,027 1,592 |

Arihant Research Desk

Email: instresearch@arihantcapital.com

Tel.: 022-42254800

| Head Office | Registered Office |
|--|-------------------------|
| #1011, Solitaire Corporate Park | Arihant House |
| Building No. 10, 1 st Floor | E-5 Ratlam Kothi |
| Andheri Ghatkopar Link Road | Indore - 452003, (M.P.) |
| Chakala, Andheri (E) | Tel: (91-731) 3016100 |
| Mumbai – 400093 | Fax: (91-731) 3016199 |
| Tel: (91-22) 42254800 | |
| Fax: (91-22) 42254880 | |

| Stock Rating Scale | Absolute Return |
|--------------------|-----------------|
| BUY | >20% |
| ACCUMULATE | 12% to 20% |
| HOLD | 5% to 12% |
| NEUTRAL | -5% to 5% |
| REDUCE | -5% to -12% |
| SELL | <-12% |

| Research Analyst Registration No. | Contact | Website | Email Id |
|-----------------------------------|-------------------------|------------------------|---------------------------------|
| INH000002764 | SMS: 'Arihant' to 56677 | www.arihantcapital.com | instresearch@arihantcapital.com |

Disclaimer: This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

Arihant Capital Markets Ltd. 1011, Solitaire Corporate park, Building No. 10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E) Tel. 022-42254800Fax. 022-42254880